Michael T. Deavers
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Michael T. Deavers has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
Anais Malpica
From the Departments of Pathology (Drs Posligua, Malpica, Liu, and Deavers) and Gynecologic Oncology (Dr Brown), The University of Texas M. D. Anderson Cancer Center, Houston
5 shared publications- Anais Malpica
Department of Pathology, The University of Texas MD Anderson Cancer Center, PO Box 301439, Houston, TX 77230-1429, USA
3 shared publications Jinsong Liu
From the Departments of Pathology (Drs Posligua, Malpica, Liu, and Deavers) and Gynecologic Oncology (Dr Brown), The University of Texas M. D. Anderson Cancer Center, Houston
3 shared publications- Ralph S. Freedman
Department of Gynecologic Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
3 shared publications - David M. Gershenson
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
2 shared publications Elvio G Silva
Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
2 shared publications
Latest Publications
- 4 February 2014
- Published by Springer Nature in Skeletal Radiology
- Vol. 43 (7) , 1007-1011
Spontaneous hip dislocation secondary to intraarticular neurofibroma: a case report
- 4 February 2014
- Published by Springer Nature in Skeletal Radiology
- Vol. 43 (7) , 1007-1011
Spontaneous hip dislocation secondary to intraarticular neurofibroma: a case report
- 1 January 2014
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 69 (1) , 26-27
A 2-Stage Ovarian Cancer Screening Strategy Using the Risk of Ovarian Cancer Algorithm (ROCA) Identifies Early-Stage Incident Cancers and Demonstrates High Positive Predictive Value
Diagnosis of ovarian cancer at an early stage is associated with a rate of survival of 75% or higher. Most women with this cancer are diagnosed at a late stage when long-term cure rates are less than 30%. Currently, there are no proven screening strategies for the early detection for ovarian cancer. A definitive diagnosis requires invasive surgery and removal of the ovaries. Any screening strategy for this cancer must minimize false positives to decrease the number of unnecessary operations. Measurement of fixed cut-point levels of carbohydrate antigen 125 (CA-125), an ovarian tumor marker, and an abnormal transvaginal ultrasound (TVS) finding have been used as a screening strategy for ovarian cancer; however, neither has sufficient specificity. Recent studies have shown that the sensitivity and specificity of screening with CA-125 can be improved when rising CA-125 levels, even within a reference range, are used to prompt TVS. The Risk of Ovarian Cancer Algorithm (ROCA) is a computer algorithm that quantifies the risk of developing ovarian cancer in postmenopausal women at normal risk who are screened for this cancer. The aim of this single-arm prospective study was to determine if a 2-step strategy that incorporates change of CA-125 levels over time and age has sufficient specificity and positive predictive value for estimating the risk of ovarian cancer in a population of postmenopausal women at normal risk. A small fraction of women with high-risk ROCA scores were referred for TVS as the second step of this strategy. Participants had an annual CA-125 blood test. Based on the ROCA score, women were triaged into the 1 of following 3 groups: a low-risk group (which would require return in 1 year for a CA-125 test), an intermediate-risk group (which would require women to repeat their CA-125 test in 3 months), or a high-risk group (which would require TVS and referral to a gynecologic oncologist). The decision for surgery was made by the gynecologic oncologist. The final study sample was composed of 4051 participants who were evaluated over 11 years (2001–2011). The average annual rate for triage to a CA-125 test in 3 months (intermediate-risk group) was 5.8%, and the average annual rate for triage to TVS and review by a gynecologic oncologist (high-risk group) was 0.9%. Ten women with suspicious TVS findings underwent surgery: 3 of these women had benign ovarian tumors, 2 had stage I ovarian serous tumors of low malignant potential, 4 had early-stage high-grade invasive ovarian cancers, and 1 patient was subsequently found to have endometrial cancer. The specificity with the 2-stage screening strategy was 99.9% (95% confidence interval [CI], 99.7%–100%). All 4 of the invasive ovarian cancers were found in women with normal, low-risk ROCA scores who had returned for annual CA-125 tests for at least 3 years prior to the rising CA-125 values. These data show that ROCA followed by TVS identifies early-stage incident ovarian cancer with excellent specificity and positive predictive value in a population of postmenopausal women at normal risk for ovarian cancer.
- 1 January 2014
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 69 (1) , 26-27
A 2-Stage Ovarian Cancer Screening Strategy Using the Risk of Ovarian Cancer Algorithm (ROCA) Identifies Early-Stage Incident Cancers and Demonstrates High Positive Predictive Value
Diagnosis of ovarian cancer at an early stage is associated with a rate of survival of 75% or higher. Most women with this cancer are diagnosed at a late stage when long-term cure rates are less than 30%. Currently, there are no proven screening strategies for the early detection for ovarian cancer. A definitive diagnosis requires invasive surgery and removal of the ovaries. Any screening strategy for this cancer must minimize false positives to decrease the number of unnecessary operations. Measurement of fixed cut-point levels of carbohydrate antigen 125 (CA-125), an ovarian tumor marker, and an abnormal transvaginal ultrasound (TVS) finding have been used as a screening strategy for ovarian cancer; however, neither has sufficient specificity. Recent studies have shown that the sensitivity and specificity of screening with CA-125 can be improved when rising CA-125 levels, even within a reference range, are used to prompt TVS. The Risk of Ovarian Cancer Algorithm (ROCA) is a computer algorithm that quantifies the risk of developing ovarian cancer in postmenopausal women at normal risk who are screened for this cancer. The aim of this single-arm prospective study was to determine if a 2-step strategy that incorporates change of CA-125 levels over time and age has sufficient specificity and positive predictive value for estimating the risk of ovarian cancer in a population of postmenopausal women at normal risk. A small fraction of women with high-risk ROCA scores were referred for TVS as the second step of this strategy. Participants had an annual CA-125 blood test. Based on the ROCA score, women were triaged into the 1 of following 3 groups: a low-risk group (which would require return in 1 year for a CA-125 test), an intermediate-risk group (which would require women to repeat their CA-125 test in 3 months), or a high-risk group (which would require TVS and referral to a gynecologic oncologist). The decision for surgery was made by the gynecologic oncologist. The final study sample was composed of 4051 participants who were evaluated over 11 years (2001–2011). The average annual rate for triage to a CA-125 test in 3 months (intermediate-risk group) was 5.8%, and the average annual rate for triage to TVS and review by a gynecologic oncologist (high-risk group) was 0.9%. Ten women with suspicious TVS findings underwent surgery: 3 of these women had benign ovarian tumors, 2 had stage I ovarian serous tumors of low malignant potential, 4 had early-stage high-grade invasive ovarian cancers, and 1 patient was subsequently found to have endometrial cancer. The specificity with the 2-stage screening strategy was 99.9% (95% confidence interval [CI], 99.7%–100%). All 4 of the invasive ovarian cancers were found in women with normal, low-risk ROCA scores who had returned for annual CA-125 tests for at least 3 years prior to the rising CA-125 values. These data show that ROCA followed by TVS identifies early-stage incident ovarian cancer with excellent specificity and positive predictive value in a population of postmenopausal women at normal risk for ovarian cancer.
- 27 January 2013
- Published by Springer Nature in Skeletal Radiology
- Vol. 42 (5) , 725-728
Posttraumatic intramedullary osteochondroma: Report of a case
We present a rare osteochondroma, which instead of being the usual exophytic growth outside bone, grew inward into the medullary cavity of distal femur in a patient with prior trauma to his knee. Except for its intramedullary location, the benign tumor had all the classic radiographic and pathologic features of typical osteochondroma.
- 27 January 2013
- Published by Springer Nature in Skeletal Radiology
- Vol. 42 (5) , 725-728
Posttraumatic intramedullary osteochondroma: Report of a case
We present a rare osteochondroma, which instead of being the usual exophytic growth outside bone, grew inward into the medullary cavity of distal femur in a patient with prior trauma to his knee. Except for its intramedullary location, the benign tumor had all the classic radiographic and pathologic features of typical osteochondroma.
- 1 June 2012
- Published by Elsevier in Gynecologic Oncology
- Vol. 125 (3) , 661-666
Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum
- 1 June 2012
- Published by Elsevier in Gynecologic Oncology
- Vol. 125 (3) , 661-666
Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum
- 26 May 2012
- Published by Springer Nature in Skeletal Radiology
- Vol. 41 (11) , 1475-1478
Enchondroma with secondary aneurysmal bone cyst
An enchondroma with complex cystic changes of the proximal femur is described in a 13-year-old male. The case illustrates a unique presentation of an enchondroma and reinforces the importance of considering the presence of secondary aneurysmal bone cysts in both benign and malignant lesions of bone.
- 26 May 2012
- Published by Springer Nature in Skeletal Radiology
- Vol. 41 (11) , 1475-1478
Enchondroma with secondary aneurysmal bone cyst
An enchondroma with complex cystic changes of the proximal femur is described in a 13-year-old male. The case illustrates a unique presentation of an enchondroma and reinforces the importance of considering the presence of secondary aneurysmal bone cysts in both benign and malignant lesions of bone.
- 1 October 2011
- Published by Elsevier in Gynecologic Oncology
- Vol. 123 (1) , 13-18
The insulin-like growth factor 1 pathway is a potential therapeutic target for low-grade serous ovarian carcinoma
- 1 October 2011
- Published by Elsevier in Gynecologic Oncology
- Vol. 123 (1) , 13-18
The insulin-like growth factor 1 pathway is a potential therapeutic target for low-grade serous ovarian carcinoma
- 1 November 2008
- Published by Wiley in Archives of Pathology & Laboratory Medicine
- Vol. 132 (11) , 1821-4
Combined large cell neuroendocrine carcinoma and papillary serous carcinoma of the endometrium with pagetoid spread.
Neuroendocrine carcinomas of the endometrium are rare tumors that can be pure, combined with endometrioid adenocarcinoma, or a component of malignant mixed müllerian tumor. Recently, a case of combined small cell carcinoma and papillary serous carcinoma of the endometrium was described for the first time. We report the first case, to our knowledge, of combined large cell neuroendocrine carcinoma and papillary serous carcinoma of the endometrium, with an unusual pagetoid spread of the neuroendocrine component into normal endometrial and endocervical glands. The endometrial carcinoma had a small serous component, but most of the tumor was characterized by solid sheets of medium to large cells with abundant mitotic figures, numerous apoptotic bodies, and foci of necrosis. This component was diffusely positive for neuroendocrine markers. Following surgery, the patient was treated with radiation therapy and chemotherapy. She was without evidence of progression at 5 months of follow-up.
- 1 November 2008
- Published by Wiley in Archives of Pathology & Laboratory Medicine
- Vol. 132 (11) , 1821-4
Combined large cell neuroendocrine carcinoma and papillary serous carcinoma of the endometrium with pagetoid spread.
Neuroendocrine carcinomas of the endometrium are rare tumors that can be pure, combined with endometrioid adenocarcinoma, or a component of malignant mixed müllerian tumor. Recently, a case of combined small cell carcinoma and papillary serous carcinoma of the endometrium was described for the first time. We report the first case, to our knowledge, of combined large cell neuroendocrine carcinoma and papillary serous carcinoma of the endometrium, with an unusual pagetoid spread of the neuroendocrine component into normal endometrial and endocervical glands. The endometrial carcinoma had a small serous component, but most of the tumor was characterized by solid sheets of medium to large cells with abundant mitotic figures, numerous apoptotic bodies, and foci of necrosis. This component was diffusely positive for neuroendocrine markers. Following surgery, the patient was treated with radiation therapy and chemotherapy. She was without evidence of progression at 5 months of follow-up.
- Open Access
- 1 November 2008
- Published by Archives of Pathology and Laboratory Medicine in Archives of Pathology & Laboratory Medicine
- Vol. 132 (11) , 1821-1824
Combined Large Cell Neuroendocrine Carcinoma and Papillary Serous Carcinoma of the Endometrium With Pagetoid Spread
Neuroendocrine carcinomas of the endometrium are rare tumors that can be pure, combined with endometrioid adenocarcinoma, or a component of malignant mixed müllerian tumor. Recently, a case of combined small cell carcinoma and papillary serous carcinoma of the endometrium was described for the first time. We report the first case, to our knowledge, of combined large cell neuroendocrine carcinoma and papillary serous carcinoma of the endometrium, with an unusual pagetoid spread of the neuroendocrine component into normal endometrial and endocervical glands. The endometrial carcinoma had a small serous component, but most of the tumor was characterized by solid sheets of medium to large cells with abundant mitotic figures, numerous apoptotic bodies, and foci of necrosis. This component was diffusely positive for neuroendocrine markers. Following surgery, the patient was treated with radiation therapy and chemotherapy. She was without evidence of progression at 5 months of follow-up.
- 1 November 2008
- Published by Archives of Pathology and Laboratory Medicine in Archives of Pathology & Laboratory Medicine
- Vol. 132 (11) , 1821-1824
Open AccessCombined Large Cell Neuroendocrine Carcinoma and Papillary Serous Carcinoma of the Endometrium With Pagetoid Spread
Neuroendocrine carcinomas of the endometrium are rare tumors that can be pure, combined with endometrioid adenocarcinoma, or a component of malignant mixed müllerian tumor. Recently, a case of combined small cell carcinoma and papillary serous carcinoma of the endometrium was described for the first time. We report the first case, to our knowledge, of combined large cell neuroendocrine carcinoma and papillary serous carcinoma of the endometrium, with an unusual pagetoid spread of the neuroendocrine component into normal endometrial and endocervical glands. The endometrial carcinoma had a small serous component, but most of the tumor was characterized by solid sheets of medium to large cells with abundant mitotic figures, numerous apoptotic bodies, and foci of necrosis. This component was diffusely positive for neuroendocrine markers. Following surgery, the patient was treated with radiation therapy and chemotherapy. She was without evidence of progression at 5 months of follow-up.
- 1 April 2008
- Published by Elsevier in Laboratory Investigation
- Vol. 21 (4) , 485-490
Thyroid transcription factor-1 expression in ovarian epithelial neoplasms
- 1 April 2008
- Published by Elsevier in Laboratory Investigation
- Vol. 21 (4) , 485-490
Thyroid transcription factor-1 expression in ovarian epithelial neoplasms
- 1 February 2008
- Published by Wiley in Archives of Pathology & Laboratory Medicine
- Vol. 132 (2) , 168-74
Diagnostic problems with trophoblastic lesions.
The purpose of this review is to address some common problems involving the diagnosis of trophoblastic lesions.
- 1 February 2008
- Published by Wiley in Archives of Pathology & Laboratory Medicine
- Vol. 132 (2) , 168-74
Diagnostic problems with trophoblastic lesions.
The purpose of this review is to address some common problems involving the diagnosis of trophoblastic lesions.